- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04030637
The Diagnostic Accuracy of Using Faecal-DNA Test (COLOSAFE) for Colorectal Cancer Screening
Study Overview
Status
Detailed Description
Colorectal cancer (CRC) remains to be a leading cause of cancer mortality [1]. It induces a substantial financial burden in terms of healthcare utilization and quality-adjusted life years (QALY) lost [2]. Fecal Occult Blood Tests (FOBT) and colonoscopy were proven effective in reducing CRC mortality by 33% and 68%, respectively [3-5]. Both tests have been proposed as primary screening modalities for asymptomatic subjects by international guidelines and Asia Pacific consensus statements [6-8]. However, colonoscopy has a low compliance rate at approximately 20% in Chinese populations, and has been perceived by screening participants as invasive, expensive and inconvenient due to the need for bowel preparation [9, 10]. In addition, the accuracy of FOBT is limited and its adherence declined sharply over time [11, 12]. Hence, the recent decade witnessed a rapid development of non-invasive biomarkers to detect CRC.
Faecal-DNA test is a novel screening test for CRC, using molecular techniques to identify CRC-relevant biomarkers in stool. One of its toolkits, branded 'ColoGuard' (sDNA, Exact Sciences), was first approved by the FDA in 2014 for its application in clinical practice [13]. It consists of quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, and β-actin, and a hemoglobin immunoassay [13], which has been widely promoted in US. In 2016, it was endorsed by the United States Preventive Service Task Force (USPSTF) as one of the recommended screening tests [14].
Recently, a test kit named 'COLOSAFE' (or namedChang An Xin) has been developed as a faecal-DNA product targeted to improve diagnostic accuracy of CRC screening [15]. It is a stool test of methylated SDC2 for detection of CRC. This stool test of methylated SDC2 detected 81.1% of CRC and 58.2% of adenomas at a specificity of 93.3%. SDC2 is also named fibroglycan, encoding a type I trans-membrane heparansulfate proteoglycan. In certain cancers, hypermethylation of SDC2 had been reported. Recent studies showed that methylated SDC2 was detected at high frequency in blood from CRC patients [16, 17]. As tumor cells are exfoliated into the gut lumen earlier than vascular invasion when CRC develops [18], faecal sample could represent a more suitable specimen than plasma for detection of early cancer.
A recent study involving 1,200 subjects from 2015 to 2017 by the Sixth Affiliated Hospital of Sun Yat-sen University, Nanfang Hospital of Southern Medical University and Shandong Cancer Hospital showed that the 'COLOSAFE' test kit attained a sensitivity of 85% while maintaining a specificity of 98% (unpublished data). Because of its novelty, the 'COLOSAFEtest kit was recognized as a 'creative medical apparatus' by the National CFDA in March 2017. In June 2017, the project 'Screening and intervention research of Chinese CRC' (2017YFC 1308800) was launched with national key project for non-communicable disease control. Nevertheless, there are limitations with the design of the original study [15]. For instance, it involved a small, single-centre that recruited a homogeneous sample of individuals only. An important knowledge gap exists and additional clinical trials are required to further validate its diagnostic accuracy in other populations.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Ming Yeung Ho
- Phone Number: 2637 1398
- Email: andrewho@cuhk.edu.hk
Study Contact Backup
- Name: Yuen Tung Lam
- Phone Number: 26370355
- Email: thomaslam@cuhk.edu.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Prince of Wales Hospital
-
Contact:
- Ming Yeung HO
- Phone Number: 26371398
- Email: andrewho@cuhk.edu.hk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- CRC patients, individuals with normal colonoscopy findings, or patients with other colorectal pathologies;
- Chinese subjects aged 45 to 79 years living in Hong Kong for most of the time in the past 5 years;
- Having received colonoscopy within 8 days to 3 months before enrolment in the study);
- Absence of medical conditions that render the subject unable to comprehend the study;
- Willing to provide informed consent;
- Willing to provide faecal sample for laboratory investigation in the present study.
Exclusion Criteria:
- History of major chronic illnesses which are serious (including those with respiratory, cardiac, renal, liver or immune function impairment or requiring long-term immunosuppressive therapy);
- Previous history of inflammatory bowel diseases or digestive cancers other than CRC;
- History of colorectal resection for any reason other than sigmoid diverticula;
- Had a surgery or an invasive procedure within the past 3 months;
- Received chemotherapy or radiotherapy with the past 3 months;
- Had participated in any interventional clinical study within the previous 30 days.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
CRC cases
samples will be collected from subjects with known diagnosis of colorectal cancer
|
Healthy cases
samples will be collected from healthy subjects with normal colonoscopy findings
|
Cases with pathologies
samples will be collected from subjects whose colonoscopies showed other pathologies (e.g.
inflammatory polyps, adenomas, diverticular diseases)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Accuracy of COLOSAFE
Time Frame: 1 year
|
Sensitivity, specificity, positive predictive value and negative predictive value in detection of CRC by COLOSAFE
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Protocol_v21_20190110
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on To Evaluate the Sensitivity and Specificity of a Test Kit in Hong Kong
-
Sheba Medical CenterUnknownTo Demonstrate That the Closed Loop System Can be Used Safely Over a Few Consecutive Days. | To Assess Effectiveness in Maintaining Patients' Glucose Levels in the Target Range of 70 to 180 mg/dl, Measured by Blood Glucose Sensor. | To Evaluate the User Experience With a Closed Loop...Israel
-
Hadassah Medical OrganizationCompletedTo Evaluate Effectiveness of the Gait Trainer in Increasing the Functionality and Spatiotemporal Parameters of Gait of 4 Patients.Israel
-
Ain Shams UniversityUnknownTo Evaluate the Impact of the Vaginal Ph and Acidification of Vaginal Misoprostol on Its Efficacy in Facilitating Induction of Mid-trimester Abortion.United States
-
Assistance Publique Hopitaux De MarseilleUnknownthe Coagulolytic Balance | the Mortality Rate | the Performance Used to Evaluate the Principal Objective Are Technical Performances, Sensibility and Specificity of the TestsFrance
-
Shanghai General Hospital, Shanghai Jiao Tong University...Not yet recruitingTo Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMD
-
Tomey CorporationCompletedEvaluate the Agreement and Precision of Device SS-1000 and the Predicate Device the Pentacam in a Reproducibility and Repeatability TrialJapan
-
Tianjin University of Traditional Chinese MedicineNational Basic Research Program, ChinaCompletedto Evaluate the Effectiveness of Acupucnture in the Management of Chemotherapy-induced Nausea and VomitingChina
-
Jinnah Sindh Medical UniversityAl Khidmat Hospital Nazimabad Karachi; Medics Laboratories (Pvt.) Ltd.CompletedThe Main Focus of This Study is to Evaluate the Safety of Zingiber Officinale L. Tablets as Hypolipidemic Agent in Hypertensive PatientsPakistan
-
Johannes Gutenberg University MainzUnknownFocus of the Study is to Evaluate a New Developed Deep-learning Computer-aided Detection System in Combination With LCI for Colorectal Polyp DetectionGermany
-
University Hospital, Clermont-FerrandInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement and other collaboratorsTerminatedThe Objective is to Confirm the Role of Gluten in Triggering the Digestive and Extradigestive Symptoms of NCGSFrance